TY - JOUR
T1 - Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer
T2 - A prospective study
AU - Vargas, Hebert Alberto
AU - Akin, Oguz
AU - Shukla-Dave, Amita
AU - Zhang, Jingbo
AU - Zakian, Kristen L.
AU - Zheng, Junting
AU - Kanao, Kent
AU - Goldman, Debra A.
AU - Moskowitz, Chaya S.
AU - Reuter, Victor E.
AU - Eastham, James A.
AU - Scardino, Peter T.
AU - Hricak, Hedvig
PY - 2012/11
Y1 - 2012/11
N2 - Purpose: To prospectively evaluate diagnostic performance of T2- weighted magnetic resonance (MR) imaging and MR spectroscopic imaging in detecting lesions stratified by pathologic volume and Gleason score in men with clinically determined low-risk prostate cancer. Materials and Methods: The institutional review board approved this prospective, HIPAA-compliant study. Written informed consent was obtained from 183 men with clinically low-risk prostate cancer (cT1-cT2a, Gleason score ≤ 6 at biopsy, prostatespecific antigen [PSA] level < 10 ng/mL [10 mg/L]) undergoing MR imaging before prostatectomy. By using a scale of 1-5 (score 1, definitely no tumor; score 5, definitely tumor), two radiologists independently scored likelihood of tumor per sextant on T2-weighted images. Two spectroscopists jointly recorded locations of lesions with metabolic features consistent with tumor on MR spectroscopic images. Whole-mount step-section histopathologic analysis constituted the reference standard. Diagnostic performance at sextant level (T2-weighted imaging) and detection sensitivities (T2-weighted imaging and MR spectroscopic imaging) for lesions of 0.5 cm3 or larger were calculated. Results: For T2-weighted imaging, areas under the receiver operating characteristic curves for sextant-level detection were 0.77 (reader 1) and 0.82 (reader 2). For lesions of ≥0.5 cm3 and <1 cm3, sensitivities were significantly lower when the lesion Gleason score was ≤6 (0.44 [reader 1] and 0.61 [reader 2]) rather than when the Gleason score was ≥7 (0.73, P = .02 [reader 1]; and 0.84, P = .05 [reader 2]). For lesions of ≥1 cm3, lesion Gleason score did not significantly affect sensitivity (0.83 [reader 1] and 1.00 [reader 2] for Gleason score ≤ 6 vs 0.82 and 0.92 for Gleason score ≥ 7; P ≥ .07). MR spectroscopic imaging sensitivity was low and was not significantly affected by pathologic lesion volume or Gleason score. Conclusion: In men with clinically low-risk prostate cancer, detection of lesions of <1 cm3 with T2-weighted imaging is significantly dependent on lesion Gleason score; detection of lesions of ≥1 cm3 is significantly better than detection of smaller lesions and is not affected by lesion Gleason score. The role of MR spectroscopic imaging alone in this population is limited.
AB - Purpose: To prospectively evaluate diagnostic performance of T2- weighted magnetic resonance (MR) imaging and MR spectroscopic imaging in detecting lesions stratified by pathologic volume and Gleason score in men with clinically determined low-risk prostate cancer. Materials and Methods: The institutional review board approved this prospective, HIPAA-compliant study. Written informed consent was obtained from 183 men with clinically low-risk prostate cancer (cT1-cT2a, Gleason score ≤ 6 at biopsy, prostatespecific antigen [PSA] level < 10 ng/mL [10 mg/L]) undergoing MR imaging before prostatectomy. By using a scale of 1-5 (score 1, definitely no tumor; score 5, definitely tumor), two radiologists independently scored likelihood of tumor per sextant on T2-weighted images. Two spectroscopists jointly recorded locations of lesions with metabolic features consistent with tumor on MR spectroscopic images. Whole-mount step-section histopathologic analysis constituted the reference standard. Diagnostic performance at sextant level (T2-weighted imaging) and detection sensitivities (T2-weighted imaging and MR spectroscopic imaging) for lesions of 0.5 cm3 or larger were calculated. Results: For T2-weighted imaging, areas under the receiver operating characteristic curves for sextant-level detection were 0.77 (reader 1) and 0.82 (reader 2). For lesions of ≥0.5 cm3 and <1 cm3, sensitivities were significantly lower when the lesion Gleason score was ≤6 (0.44 [reader 1] and 0.61 [reader 2]) rather than when the Gleason score was ≥7 (0.73, P = .02 [reader 1]; and 0.84, P = .05 [reader 2]). For lesions of ≥1 cm3, lesion Gleason score did not significantly affect sensitivity (0.83 [reader 1] and 1.00 [reader 2] for Gleason score ≤ 6 vs 0.82 and 0.92 for Gleason score ≥ 7; P ≥ .07). MR spectroscopic imaging sensitivity was low and was not significantly affected by pathologic lesion volume or Gleason score. Conclusion: In men with clinically low-risk prostate cancer, detection of lesions of <1 cm3 with T2-weighted imaging is significantly dependent on lesion Gleason score; detection of lesions of ≥1 cm3 is significantly better than detection of smaller lesions and is not affected by lesion Gleason score. The role of MR spectroscopic imaging alone in this population is limited.
UR - http://www.scopus.com/inward/record.url?scp=84867911571&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867911571&partnerID=8YFLogxK
U2 - 10.1148/radiol.12120041
DO - 10.1148/radiol.12120041
M3 - Article
C2 - 22952382
AN - SCOPUS:84867911571
SN - 0033-8419
VL - 265
SP - 478
EP - 487
JO - Radiology
JF - Radiology
IS - 2
ER -
